MeiraGTx 3Q 2026: Revenue $4.81M, EPS ($0.53) — 10-Q Summary
MeiraGTx reported 3Q 2026 revenue of $4.81M, up 1074% YoY, driven by Lilly contract services and Reogen transition services. Net loss widened slightly to $51.2M. Phase 2 AQUAx2 enrollment completed; pivotal data readout expected mid-2027. MAA dossier for Bota-vec to be submitted to EMA in December 2026.
How this was made
The 30-second read
Why it matters
The earnings release provides fresh data that could trigger short‑term price movement.
Market read
Primary earnings disclosure for a micro‑cap biotech; relevance mainly to traders with exposure to MGTX.
What to watch
Potential pipeline milestones later in 2027 may offset short‑term earnings weakness.
Background
MeiraGTx filed its 10‑Q for Q3 2026, reporting a sharp revenue increase but a widening net loss.
Ticker impact
Q3 2026 revenue rose to $4.81M and EPS fell to -$0.53, with net loss widening to $51.2M.
likely pressure as the market prices in the larger loss
Revenue growth is modest and loss expansion signals higher burn, which may trigger sell‑offs.
Market effects
Highlights ongoing challenges in the gene‑therapy sector with modest contract revenue.
Limited to biotech investors; no broad regional effect.
Low global relevance beyond niche biotech space.
Counterpoint
If the Lilly contract expands, the modest revenue could be a stepping stone to larger deals.
Key entities
- companyMeiraGTx Holdings plc
Biotech firm focused on gene‑therapy platforms.
